Form 4: Rhythm Pharmaceuticals Executive Joseph Shulman Reports Stock Transactions

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• On February 1, 2025, Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, vested 3,938 restricted stock units, each representing one share of common stock.
• Following the vesting, on February 4, 2025, Shulman sold 1,281 shares of common stock at a price of $59.43 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan to cover withholding taxes related to the vesting of the restricted stock units.
• After these transactions, Shulman directly owns 2,657 shares of Rhythm Pharmaceuticals common stock and 7,874 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine stock transactions by an executive. The sale is related to tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations upon vesting of restricted stock units are a common practice across the pharmaceutical industry.
• Similar transactions are regularly reported by executives at companies like Amgen, Biogen, and Vertex Pharmaceuticals.
• The use of Rule 10b5-1 trading plans is a standard method to avoid accusations of insider trading, ensuring transactions are pre-planned and not based on current non-public information.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the pre-planned nature of the transaction mitigates potential concerns.

Key Dates

Keywords

Rhythm Pharmaceuticals, Joseph Shulman, Form 4, Stock Sale, Restricted Stock Units, Rule 10b5-1, Insider Trading, RYTM